Vascular endothelial growth factor (VEGF) is involved in non-small cell lung cancer
(NSCLC) with malignant pleural effusion (MPE), but little is known regarding the efficacy of …

Objectives Vascular endothelial growth factor plays an important role in the pathogenesis of
malignant pleural effusion (MPE). We previously showed the efficacy of bevacizumab (Bev) …

Background Vascular endothelial growth factor (VEGF) plays a pivotal role in the
pathogenesis of malignant pleural effusion (MPE). Here, a multicenter phase II trial to …

Purpose The presence of malignant pleural effusion (MPE) indicates a poorer prognosis for
patients with non-small-cell lung cancer (NSCLC) and impairs their quality of life. Because …

Aim: Malignant effusion is associated with high serum and plasma levels of vascular
endothelial growth factor (VEGF). There are no biomarkers of outcome for bevacizumab …

Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung
cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular …

Malignant pleural effusion (MPE) is a common complication of lung cancer with devastating
consequences. Since vascular endothelial growth factor (VEGF) has been implicated in …

Background Pleurodesis is the standard of care for non‐small cell lung cancer (NSCLC)
patients with symptomatic malignant pleural effusion (MPE). However, there is no standard …

Background VEGF is critical in the pathogenesis of malignant pleural effusion (MPE). To
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …

Background To compare the efficiency and toxicity of bevacizumab by intrapleural or
intravenous infusion in the management of malignant pleural effusion in patients with non …